Protalix BioTherapeutics, Inc.
HealthcareAMEX:PLX · New York Stock Exchange American
+$0.04 today
Vol 0.25M · Avg 0.83M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $41.7M |
| Short-term Investments | $10.1M |
| Receivables | $2.9M |
| Inventory | $30.5M |
| Other Current | $1.1M |
| Total Current Assets | $86.4M |
| PP&E (Net) | $12.9M |
| Tax Assets | $2.4M |
| Other Non-current | $589.0K |
| Total Non-current Assets | $16.0M |
| Total Assets | $102.3M |
Analysis
Selected assets total $102.3M for Latest. The largest visible component is Cash & Equivalents at $41.7M, about 40.8% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $14.7M -25.7% | $19.8M -16.4% | $23.6M +38.1% | $17.1M -56.1% | $39.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $15.6M +3.5% | $15.1M -28.0% | $20.9M +312.8% | $5.1M | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $8.8M +203.9% | $2.9M -44.8% | $5.3M +15.0% | $4.6M +33.2% | $3.4M | $533.8M | $399.4M | -$1.7B |
| Inventory | $25.7M +21.1% | $21.2M +11.5% | $19.0M +13.3% | $16.8M -6.4% | $18.0M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $1.4M +141.1% | $596.0K -2.5% | $611.0K +14.0% | $536.0K +41.1% | $380.0K | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $66.7M +11.0% | $60.1M -14.1% | $69.9M +55.8% | $44.9M -27.2% | $61.7M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $12.6M +25.5% | $10.0M -7.9% | $10.9M +12.9% | $9.6M -2.8% | $9.9M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $2.5M -11.9% | $2.9M -7.6% | $3.1M | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $578.0K +25.1% | $462.0K -12.5% | $528.0K -58.3% | $1.3M -39.0% | $2.1M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $15.7M +17.5% | $13.3M -8.0% | $14.5M +33.0% | $10.9M -9.1% | $12.0M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $82.3M +12.2% | $73.4M -13.0% | $84.4M +51.4% | $55.8M -24.3% | $73.7M | $13.3B | $11.9B | $10.6B |
| Account Payables | $5.3M +16.0% | $4.5M +4.9% | $4.3M -26.3% | $5.9M -16.1% | $7.0M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 -100.0% | $21.7M | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $3.5M +20.9% | $2.9M +442.6% | $530.0K | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 -100.0% | $13.2M +54.1% | $8.6M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $2.3M +27.5% | $1.8M -63.4% | $4.9M -55.3% | $11.1M +634.1% | $1.5M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $26.5M +3.5% | $25.6M -43.7% | $45.5M +40.4% | $32.4M -2.3% | $33.2M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 -100.0% | $28.2M +1.1% | $27.9M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 -100.0% | $11.8M | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $661.0K +18.2% | $559.0K -21.7% | $714.0K -56.5% | $1.6M -33.6% | $2.5M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $7.6M +65.7% | $4.6M -14.1% | $5.3M -84.3% | $34.0M -26.9% | $46.5M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $34.1M +12.9% | $30.2M -40.6% | $50.9M -23.4% | $66.4M -16.7% | $79.7M | $14.7B | $3.7B | $9.6B |
| Common Stock | $80.0K +5.3% | $76.0K +4.1% | $73.0K +35.2% | $54.0K +17.4% | $46.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$385.0M -1.7% | -$378.4M +0.8% | -$381.5M +2.1% | -$389.9M -4.0% | -$374.9M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $0 | $0 | $0 | $0 | $0 | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $48.2M +11.6% | $43.2M +28.7% | $33.6M +415.5% | -$10.6M -76.3% | -$6.0M | $9.1B | $7.7B | $3.3B |
| Total Debt | $8.3M +50.6% | $5.5M -80.0% | $27.7M -17.3% | $33.5M +0.0% | $33.5M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$6.4M +55.3% | -$14.2M -450.9% | $4.1M -75.2% | $16.4M +396.7% | -$5.5M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
$1.12B
Genfit S.A.
GNFT
$445.68M
OmniAb, Inc.
NASDAQ:OABI
$270.34M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Coherus Oncology, Inc.
NASDAQ:CHRS
$171.37M
MediWound Ltd.
NASDAQ:MDWD
$154.46M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Neonc Technologies Holdings, Inc.
NASDAQ:NTHI
$94.98M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does PLX have?
Protalix BioTherapeutics, Inc. (PLX) reported $14.68M in cash and equivalents in fiscal 2025.
How much debt does PLX carry?
Protalix BioTherapeutics, Inc. (PLX) reported $8.32M of total debt, with net debt of -$6,359,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.